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The tumor suppressor PTEN is a putative negative
regulator of the phosphatidylinositol 3-kinase/Akt path-
way. Exposure to Zn2 ions induces Akt activation, sug-
gesting that PTEN may be modulated in this process.
Therefore, the effects of Zn2 on PTEN were studied in
human airway epithelial cells and rat lungs. Treatment
with Zn2 resulted in a significant reduction in levels of
PTEN protein in a dose- and time-dependent fashion in
a human airway epithelial cell line. This effect of Zn2
was also observed in normal human airway epithelial
cells in primary culture and in rat airway epithelium in
vivo. Concomitantly, levels of PTEN mRNA were also
significantly reduced by Zn2 exposure. PTEN phospha-
tase activity evaluated by measuring Akt phosphoryla-
tion decreased after Zn2 treatment. Pretreatment of
the cells with a proteasome inhibitor significantly
blocked zinc-induced reduction of PTEN protein as well
as the increase in Akt phosphorylation, implicating the
involvement of proteasome-mediated PTEN degrada-
tion. Further study revealed that Zn2-induced ubiquiti-
nation of PTEN protein may mediate this process. A
phosphatidylinositol 3-kinase inhibitor blocked PTEN
degradation induced by Zn2, suggesting that phos-
phatidylinositol 3-kinase may participate in the regula-
tion of PTEN. However, both the proteasome inhibitor
and phosphatidylinositol 3-kinase inhibitor failed to
prevent significant down-regulation of PTEN mRNA ex-
pression in response to Zn2. In summary, exposure to
Zn2 ions causes PTEN degradation and loss of function,
which is mediated by an ubiquitin-associated proteo-
lytic process in the airway epithelium.
PTEN1 (phosphatase and tensin homolog deleted on chromo-
some 10) was discovered in 1997 as a new major tumor sup-
pressor encoded by a gene localized to human chromosome
10q23 region (1, 2). Deletions or somatic mutations within the
PTEN gene have been observed in many primary human can-
cers, tumor cell lines, and several familial cancer predisposi-
tion disorders (3, 4). It is now known that PTEN plays critical
roles not only in suppressing cancer but also in embryonic
development, cell migration, cell signaling, and apoptosis
(5–12).
PTEN protein consists of 403 amino acids. It displays high
homology in its NH2-terminal region to dual specificity phos-
phatases and also to tensin and auxilin (1, 2, 10, 13). The
COOH terminus is most likely regulatory in nature and is
composed of three subdomains: a C2 domain that has been
implicated in phospholipid-binding; two tandem PEST do-
mains that regulate PTEN protein stability; and a PDZ-binding
domain that associates with PDZ-containing proteins (14–18).
Although PTEN has phosphatase activity in vitro against both
lipid and protein substrates (5, 12, 19, 20), its primary physi-
ological target appears to be a phospholipid rather than a
phosphoprotein: specifically, the D3-phosphate group of phos-
phatidylinositol 3, 4, 5-trisphosphate (PIP3) (13, 21–24). PIP3 is
specifically produced from phosphatidylinositol 4, 5-bisphos-
phate by phosphatidylinositol 3-kinase (PI3K), which is acti-
vated by cell receptors including various tyrosine kinase
growth factor receptors and integrins (25–27). Accumulation of
PIP3 further results in the activation of the serine-threonine
protein kinase B/Akt through the recruitment of PI3K-depend-
ent serine/threonine kinases (28–30), subsequently modulating
both proliferative and apoptotic signals (10, 31). Thus, by de-
phosphorylating PIP3, PTEN antagonizes growth-promoting
and antiapoptotic pathways mediated by PI3K/Akt signaling
(32–34).
Zinc is an essential micronutrient with multiple structural
and regulatory cellular functions (35) but also a common air-
borne metallic contaminant that may contribute to the health
effects of ambient and occupational air pollution (36–39). There
has been a recent increase in interest in zinc-induced intracel-
lular signaling (40). Zn2 ions have been shown to activate the
signaling pathways involving the receptor or non-receptor
tyrosine kinases, Ras/mitogen-activated protein kinases
(MAPKs) (41–43), and the PI3K/Akt/p70 S6 kinase pathway
(44) and to inhibit the activity of protein tyrosine phosphatases
(45). In contrast to the effects of Zn2 on cell signaling, over-
expression of PTEN has opposite effects, such as blocking
downstream signaling of EGF receptor including the Ras/MEK/
MAPK cascade and antagonizing PI3K/Akt signaling (5, 20).
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This suggested the possibility that Zn2 exposure decreased
PTEN activity. Our study investigated the effects of Zn2 treat-
ment on PTEN in human airway epithelial cells. We report
here that Zn2 exposure causes a significant decrease in PTEN
protein levels and activity through a proteolytic mechanism
that depends on PI3K and leads to Akt activation.
EXPERIMENTAL PROCEDURES
Cell Culture and in Vitro Exposure—The BEAS-2B (subclone S6) cell
line was derived by transforming human bronchial cells with an ade-
novirus 12-simian virus 40 construct (46). BEAS-2B cells (passages
70–80) were grown to confluence on tissue culture-treated Costar 6- or
12-well plates in keratinocyte basal medium supplemented with 30
g/ml bovine pituitary extract, 5 ng/ml human EGF, 500 ng/ml hydro-
cortisone, 0.1 mM ethanolamine, 0.1 mM phosphoethanolamine, and 5
ng/ml insulin, as described previously (43). Cells were placed in kera-
tinocyte basal medium (without supplements) for 20–22 h before treat-
ment with zinc sulfate (Sigma).
Normal human bronchial epithelial cells (passages 2–3) were ob-
tained from normal adult volunteers by transbronchoscopic brush bi-
opsy of mainstem bronchi, conducted while following a protocol ap-
proved by the Committee on the Protection of the Rights of Human
Subjects at the University of North Carolina at Chapel Hill (45). Nor-
mal human bronchial epithelial cells were plated in supplemented
bronchial epithelial cell basal medium (0.5 ng/ml human epidermal
growth factor, 0.5 g/ml hydrocortisone, 5 g/ml insulin, 10 g/ml
transferrin, 0.5 g/ml epinephrine, 6.5 ng/ml triiodothyronine, 50 g/ml
gentamycin, 50 ng/ml amphotericin-B, 52 g/ml bovine pituitary ex-
tract, and 0.1 ng/ml retinoic acid) grown to confluence and then cultured
with bronchial epithelial cell basal medium deprived of epidermal
growth factor for 12–16 h before challenge with zinc sulfate.
Immunoprecipitation—BEAS-2B cells pretreated with MG132 were
stimulated with Zn2 for 1 h. Cells treated with different doses of Zn2
were lysed with RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxy-
cholate, and 0.1% SDS in phosphate-buffered saline, pH 7.4) containing
0.1 mM vanadyl sulfate and protease inhibitors (0.5 mg/ml aprotinin,
0.5 mg/ml trans-epoxy succinyl-L-leucylamido-(4-guanidino)butane (E-
64), 0.5 mg/ml pepstatin, 0.5 mg/ml bestatin, 10 mg/ml chymostatin,
and 0.1 ng/ml leupeptin). Cell lysates (300 g) were precleared with
protein A-agarose and then incubated with agarose-conjugated ubiq-
uitin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 4 °C
overnight. The precipitates were washed with cold RIPA buffer before
immunoblotting using a murine monoclonal anti-human PTEN anti-
body (Cascade Bioscience, Winchester, MA).
Immunoblotting—Cells with or without pretreatment of pharmaco-
logical inhibitors were treated with Zn2 and then lysed in RIPA buffer.
Cleared cell lysates or immunoprecipitates were subjected to SDS-PAGE,
as described before (42). Proteins were transferred onto nitrocellulose
membrane. Membrane was blocked with 5% non-fat milk, washed briefly,
incubated with antibodies against human PTEN (Cascade Bioscience),
phospho-specific Akt and Akt (Cell Signaling Technology, Beverly, MA),
and -actin (USBiological, Swampscott, MA), respectively, at 4 °C over-
night followed by incubating with corresponding horseradish peroxidase-
conjugated secondary antibody for 1 h at room temperature. Immunoblot
images were detected using chemiluminescence reagents (Pierce) and the
Gene Gynome Imaging System (Syngene, Frederick, MD).
Real-time Reverse Transcriptase-PCR—BEAS-2B cells grown to con-
fluence were exposed to 50 M Zn2. Cells were lysed with 4 M guani-
dine thiocyanate (Roche Applied Science), 50 mM sodium citrate, 0.5%
sarkoyl, and 0.01 M dithiothreitol. Total RNA (200 ng) was isolated
using RNeasy kit (Qiagen Inc., Valencia, CA) and reverse-transcribed
into cDNA. Quantitative PCR was performed using TaqMan Universal
PCR Master Mix (Roche Applied Science) and an ABI Prism 7700
sequence detector (Applied Biosystems, Foster City, CA) (47). PTEN
mRNA levels were normalized using the expression of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA. Relative amounts of
PTEN and GAPDH mRNA were based on standard curves prepared by
serial dilution of cDNA from human BEAS-2B cells. The following
oligonucleotide primers and probes were used: PTEN, 5-TGT TGT TTC
ACA AGA TGA TGT TTG A-3 (sense), 5-CGT CGT GTG GGT CCT
GAA TT-3 (antisense), 5-ACT ATT CCA ATG TTC AGT GGC GGA
ACT TGC-3 (probe); GAPDH, 5-GAA GGT GAA GGT CGG AGT C-3
(sense), 5-GAA GAT GGT GAT GGG ATT TC-3 (antisense), 5-CAA
GCT TCC CGT TCT CAG CC-3 (probe). In addition, PTEN mRNA
expression was also determined in cells pretreated with vehicle or
inhibitors (MG132 or LY294002) prior to zinc exposure according to the
same procedure.
Immunohistochemistry—Male Sprague-Dawley rats (60 days old)
were anesthetized with halothane and instilled with either 0.5 ml of
saline or 0.5 ml of 50 M zinc sulfate in saline. 24 h after instillation, the
lungs of euthanized rats were fixed with 10% formalin (35 ml/kg of body
weight) (Fisher). The immunochemical staining was conducted as de-
scribed before (48). Tissue sections were mounted on silane-treated
slides (Fisher) and air-dried overnight. The slides were heat-fixed at
600 °C in a slide dryer (Shandon Lipshaw, Pittsburgh, PA) and then
followed by deparaffinization and hydration to 95% alcohol (xylene for
10 min, absolute alcohol for 5 min, and 95% alcohol for 5 min). Endog-
enous peroxidase activity was blocked with H2O2 in absolute methanol
(30% H2O2 in 30 ml of methanol) for 8 min. Slides were rinsed in 95%
alcohol for 2 min, placed in deionized H2O, and washed in phosphate-
buffered saline. After treatment with Cyto Q Background Buster (In-
novex Biosciences) for 10 min, slides were incubated with mouse anti-
human PTEN antibody (Cascade Bioscience, Winchester, MA) diluted
1:100 in 1% bovine serum albumin for 45 min at 37 °C followed by
incubation with biotinylated linking secondary antibody from Stat-Q
staining system (Innovex Biosciences) for 10 min at room temperature
and washed with phosphate-buffered saline, and peroxidase enzyme
label from Stat-Q Staining System was applied. Tissue sections were
developed with 3,3-diaminobenzidine tetrahydrochloride and counter-
stained with hematoxylin. Coverslips were applied using a permanent
mounting medium.
Statistics—Data are presented as means  S.E. Unpaired Student’s
t tests with conferring correction were used for pairwise comparison.
RESULTS
Reduction of PTEN Protein Levels in Human Airway Epithe-
lial Cells Exposed to Zn2—Previous studies showed that Zn2-
induced activation of the PI3K/Akt signaling pathway (44)
suggested that this metal may affect PTEN protein. To test this
assumption, PTEN protein levels were measured in human
airway epithelial cells exposed to Zn2 using Western blotting.
As shown in Fig. 1A, exposure to 50 M Zn2 for 4 and 8 h
significantly decreased PTEN protein levels in BEAS-2B cells.
Exposure of BEAS-2B cells to 50 M Zn2 for 8 h did not result
in significant alterations in cell viability, as assessed by assay
of lactate dehydrogenase activity released into the culture me-
dium (data not shown). The magnitude of the Zn2-induced
reduction in PTEN content was proportional to the concentra-
tion of Zn2 administered to the cells (Fig. 1B). PTEN protein
FIG. 1. Zn2 reduced PTEN protein level in human airway
epithelial cells. Confluent BEAS-2B cells were starved in keratinocyte
basal medium overnight before treatment with zinc sulfate. Cells were
exposed to 50 M Zn2 or vanadyl sulfate for 1, 4, and 8 h (A) or 0, 10,
25, and 50 M Zn2 for 4 h and lysed in RIPA buffer (B). Normal Human
bronchial epithelial cells grown to confluence were starved in bronchial
epithelial cell basal medium overnight and treated with 0, 10, 25, and
50 M Zn2 for 4 h and lysed in RIPA buffer (C). Cell lysates were
subjected to SDS-PAGE and immunoblotting using anti-human PTEN
antibody. PTEN protein bands were detected using enhanced chemilu-
minescence reagents. Data shown are representative of three separate
experiments.
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level in untreated cells appeared constant over time (Fig. 1A).
This finding was reproduced in normal human airway epithe-
lial cells, excluding the possibility that this effect is an artifact
of the BEAS-2B cell line (Fig. 1C). In comparison, 50 M vana-
dyl sulfate, a potent tyrosine phosphatase inhibitor (45), pro-
duced only a minimal effect on PTEN protein levels in
BEAS-2B cells (Fig. 1A). In addition, exposure of cells to 100
ng/ml EGF, a potent EGF receptor ligand (49), for 1, 2, 4, and
8 h did not show a significant effect on PTEN levels (data not
shown). These data indicated that Zn2 treatment specifically
reduced PTEN protein content in human airway epithelial
cells.
To determine whether this effect of Zn2 also occurs in air-
way epithelium in vivo, Sprague-Dawley rats were intratrache-
ally instilled with 50 M Zn2 or with saline as negative con-
trol. Both airway epithelium and alveolar macrophages in
normal rat lung tissue were positively stained for PTEN pro-
tein that predominantly existed in cytoplasm (Fig. 2A). In
contrast, PTEN protein immunostaining decreased markedly
in airway epithelium exposed to Zn2 (Fig. 2B), which was
consistent with the in vitro observations. Interestingly, PTEN
immunostaining in alveolar macrophages remained unchanged
with Zn2 exposure (Fig. 2B), suggesting that Zn2-induced
PTEN reduction may be cell type-specific.
Zn2-induced PI3K/Akt Activation in Human Airway Epithe-
lial Cells—Since PTEN antagonizes the PI3K/Akt pathway (13,
24, 27), reduction of PTEN protein levels induced by Zn2
should result in Akt activation. To further characterize the
inhibitory effect of Zn2 on PTEN-associated signaling, we next
studied the effect of Zn2 treatment on the activation of Akt in
BEAS-2B cells, as measured by the phosphorylation of Akt at
serine 473 (50). Exposure to Zn2 markedly induced Akt phos-
phorylation in BEAS-2B cells in a dose- and time-dependent
fashion (Fig. 3, A and B). Interestingly, robust Akt phosphoryl-
ation was evident 1 h after Zn2 exposure, when there was
minimal effect on the total PTEN protein level. Next, a highly
selective inhibitor of PI3K activity, LY294002 (51), was further
used to ascertain the dependence of Zn2-induced Akt phos-
phorylation on PI3K (52). Akt phosphorylation was clearly
inhibited in BEAS-2B cells pretreated with LY294002 (Fig.
3C). As vehicle control, Me2SO appeared to elevate the baseline
of Akt phosphorylation in BEAS-2B cells (Fig. 3C).
PTEN mRNA Level Was Significantly Reduced by Zn2 Ex-
posure—Reduction of PTEN protein level and function may be
associated with decreased PTEN mRNA expression in several
tumor cell lines (53). To identify the mechanisms responsible
for PTEN protein reduction, PTEN mRNA expression in zinc-
exposed cells was quantified using real-time reverse tran-
scriptase-PCR. BEAS-2B cells were exposed to different doses
of Zn2 for different periods. As shown in Fig. 4A, reduction of
PTEN mRNA expression (about 50%) was observed when cells
were exposed to 50 M Zn2. Down-regulation of PTEN mRNA
expression was only detected upon stimulation of BEAS-2B
cells with 50 M Zn2 for 8 h (Fig. 4B). Thus, in contrast to
PTEN protein levels in BEAS-2B cells, which declined as early
as 4 h of exposure, the reduction of PTEN mRNA expression
induced by Zn2 occurred after PTEN protein levels had fallen.
PTEN protein is a relatively stable protein with a half-life of
48–72 h (16). As shown in Fig. 1A, PTEN protein level in
untreated BEAS-2B cells appeared constant within 8 h of ex-
posure. Therefore, these data suggested that the down-regula-
tion of PTEN mRNA levels might not play a major role in
Zn2-induced PTEN reduction.
Proteasome-mediated PTEN Degradation in Zn2-exposed
Cells—The involvement of the proteasome in the degradation
and regulation of the function of short-lived proteins, including
oncoproteins, tumor suppressors, and cell cycle proteins, has
been extensively documented as a mechanism for post-transla-
tional regulation of protein levels (54). Therefore, we next in-
vestigated whether PTEN degradation in response to Zn2
exposure was proteasome-dependent. BEAS-2B cells were pre-
treated with a specific proteasome inhibitor, MG132 (55), and
PTEN protein levels were evaluated by Western blotting. As
shown earlier, exposure of cells to 50 M Zn2 for 8 h caused
significant decreases of PTEN protein levels and Akt activa-
tion. In comparison, pretreatment with the MG132 completely
prevented both Zn2-induced PTEN protein loss as well as Akt
activation (Fig. 5, A and B). As seen before (Fig. 3C), Me2SO
vehicle control appeared to elevate the baseline of Akt phos-
phorylation (Fig. 5B). To exclude the potential effect of MG132
on PTEN mRNA expression, PTEN mRNA expression induced
FIG. 2. Zn2 reduced PTEN protein level in airway epithelium
of rat lung. Sprague-Dawley rats were instilled intratracheally with
either 0.5 ml of saline (A) or 50 M zinc sulfate in 0.5 ml saline (B). 24 h
after instillation, rat lung was acquired after exsanguinations. After
fixation in 10% formalin, sections were cut and stained with anti-PTEN
antibody using immunohistochemistry techniques. Hematoxylin was
used for counterstain. Immunostain for PTEN can be seen in airway
epithelial cells (arrowheads) and alveolar macrophages (arrows).
FIG. 3. Activation of Akt in BEAS-2B cells exposed to Zn2.
Cells grown to confluence were starved in keratinocyte basal medium
overnight before treatment with zinc sulfate. Cells were exposed to 50
M Zn2 for 1, 4, and 8 h (A), exposed to 0, 10, 25, and 50 M Zn2 for
4 h (B), or pretreated with vehicle control (Ct) (0.1% Me2SO) or 25 M
LY294002 and challenged with 50 M Zn2 for 4 h (C). Cells were lysed
in RIPA buffer, and the lysates were subjected to SDS-PAGE and
immunoblotting using a phospho-specific Akt antibody. Data shown are
representative of three separate experiments.
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by Zn2 in BEAS-2B cells was examined using reverse tran-
scriptase-PCR as described above. Using the same exposure
conditions, MG132 had no significant effect on Zn2-induced
PTEN mRNA expression (Fig. 5C). These data strongly implied
that the 26 S proteasome played a critical role in Zn2-induced
PTEN degradation.
One of the required steps in the proteasome degradation
pathway is the formation of an ubiquitin-protein conjugate
(56). The covalent addition of multiple ubiquitin molecules to
the target protein is requisite for efficient recognition and
degradation by the 26 S proteasome (18). Therefore, the state of
ubiquitination of PTEN in Zn2-exposed cells was determined
using an immunoprecipitation assay. As shown in Fig. 6, treat-
ment of BEAS-2B cells with Zn2 induced PTEN ubiquitination
in a dose-dependent manner. These data strongly suggested
that Zn2 treatment led to ubiquitination of PTEN protein,
targeting PTEN protein to degradation by the proteasome in
airway epithelial cells.
A PI3K Inhibitor, LY294002, Blocked Zn2-induced PTEN
Degradation—The role of PTEN in antagonizing the PI3K/Akt
pathway has been well recognized (4, 13, 24). However, the
influence of the PI3K/Akt signaling pathway on PTEN has not
been investigated. Therefore, we examined the possible role of
PI3K in Zn2-induced degradation of PTEN using a specific
PI3K inhibitor, LY294002. Surprisingly, incubation with
LY294002 significantly inhibited Zn2-induced PTEN degrada-
tion (Fig. 7A). To exclude the possible effect of LY294002 on
PTEN transcription, PTEN mRNA expression in cells with or
without LY294002 pretreatment was measured using the pro-
cedure described above. As shown in Fig. 7B, LY294002 pre-
treatment produced a minimal effect on the Zn2-induced re-
duction of PTEN mRNA expression.
DISCUSSION
Although the basic concepts of PTEN structure and function
have been established and much work has been done on eluci-
dating the PTEN activity, the regulation of PTEN protein
levels via transcription, translation, and post-translational
mechanisms remains to be fully characterized (7, 12, 57). In
this study, regulation of PTEN protein was examined in trans-
formed and normal human airway epithelial cells exposed to
exogenous Zn2 ions. Our findings revealed some novel fea-
tures of PTEN regulation by Zn2 exposure. First, PTEN pro-
tein degradation can be specifically induced by Zn2 exposure
at non-toxic concentrations, in addition to the reduction of
PTEN mRNA expression; second, PTEN degradation is mainly
mediated through protein ubiquitination and subsequent pro-
teolytic degradation, although down-regulation of PTEN
mRNA expression may contribute to this process, to a lesser
extent; third, PI3K mediates the modulation of PTEN protein
levels in response to Zn2 treatment. Additionally, in compar-
ison with previous work on PTEN regulation, which mostly
employed malignant cell lines, this study shows an inducible
regulation of PTEN protein in “benign” or normal primary
human airway epithelial cells in culture by Zn2 exposure and
in rat airways in vivo.
The mechanisms that regulate PTEN protein have been
studied at the gene and protein levels. Modulation of PTEN
transcription was shown in different cell types to be associated
with an alteration of PTEN protein levels (4, 13). For example,
up-regulation of PTEN protein and mRNA expression induced
by ultraviolet light was reported to occur through the induction
of the early growth response-1 transcription factor, further
FIG. 4. Zn2 down-regulated PTEN mRNA expression in
BEAS-2B cells. Cells grown to confluence were starved overnight and
then exposed to 12.5, 25, and 50 M Zn2 for 8 h (A) or exposed to 50 M
Zn2 for 1, 4, and 8 h (B). Total RNA was extracted and reverse-
transcribed. Quantitative PCR was performed using the TaqMan
method. PTEN mRNA abundance in panel A was normalized to the
abundance of GAPDH mRNA (*, p  0.05, as compared with control).
The PTEN mRNA level in panel B was shown as fold over control.
FIG. 5. The proteasome inhibitor, MG132, blocked Zn2-in-
duced PTEN degradation and Akt phosphorylation with no sig-
nificant effect on PTEN mRNA expression in BEAS-2B cells.
Confluent BEAS-2B cells were starved overnight before pretreatment
with vehicle control (Ct) (0.1% Me2SO) or 20 M MG132 for 30 min
followed by exposure to 50 M Zn2 for 8 h. Cells were lysed with RIPA
buffer, and cell lysates were subjected to SDS-PAGE and immunoblot-
ting using an anti-human PTEN antibody (A) and a phospho-specific
Akt antibody (B). Cells were lysed with 4 M guanidine thiocyanate.
Total RNA was extracted and reverse-transcribed. Quantitative PCR
was performed as described above (C). Data shown are representative of
three separate experiments.
FIG. 6. Ubiquitination of PTEN in Zn2-exposed BEAS-2B cells.
Confluent cells were starved overnight and pretreated with 20 M
MG132 before exposure to Zn2 for 4 h. Cell lysates were immunopre-
cipitated with agarose-conjugated ubiquitin antibody. The precipitates
were subjected to SDS-PAGE and immunoblotting using anti-PTEN
antibody. Ubiquitinated PTEN bands were detected as described under
“Experimental Procedures.”
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leading to apoptosis (58). In addition, activation of nuclear
receptor peroxisome proliferator-activated receptor  induced
PTEN up-regulation by binding two response elements in the
genomic sequence upstream of PTEN (59). However, a recent
study using a breast cancer cell line showed that elevated
PTEN protein levels induced by the bone morphogenetic pro-
tein-2 (BMP-2) were not due to an increase in new PTEN
protein synthesis (57). Decreased PTEN expression both at the
mRNA and protein levels was observed in tumor-derived cell
lines and some primary tumor tissues (53). Thus, the modula-
tion of PTEN expression is complex and may be stimulus and
cell type specific. Factors that down-regulate PTEN transcrip-
tion remain to be identified (57). Transforming growth factor-
exposure was first found to decrease PTEN expression in hu-
man keratinocytes (60). In the present study, exogenous Zn2
ions were shown to clearly down-regulate PTEN protein and
mRNA levels in human airway epithelial cells. However, the
contribution of decreased PTEN mRNA levels induced by Zn2
exposure appears to be minimal in PTEN protein decline for
the following reasons: first, the half-life of normal PTEN pro-
tein is in the range of 48–72 h (16), and the decrease in PTEN
protein levels occurs earlier than the decrease in PTEN mRNA
expression following Zn2 exposure; second, proteasome inhi-
bition completely blocks Zn2-induced PTEN protein reduction
with no significant effect on PTEN mRNA expression; and
third, PI3K inhibition significantly suppresses Zn2-induced
PTEN protein degradation without affecting its mRNA
expression.
PTEN turnover in cultured COS-7 cells was reported to
depend mainly on proteasome-, not lysosome-mediated, degra-
dation (55). The enhanced PTEN degradation was preceded by
the ubiquitination of PTEN in 293T cells (18). The notion that
PTEN ubiquitination played a critical role in its degradation
was strongly supported by a recent study showing that BMP-2
stimulation inhibited PTEN protein degradation by decreasing
the association of PTEN with two proteins in the degradative
pathway, UbCH7 and UbC9 (57). Our observations in this
study also suggested that ubiquitination of PTEN played a
major role in Zn2-induced PTEN degradation. Zinc induced
PTEN ubiquitination in a dose-dependent fashion; moreover, a
specific proteasome inhibitor MG132 could markedly block
Zn2-induced PTEN degradation. Therefore, ubiquitination of
PTEN was required for Zn2-induced protein degradation and
resultant Akt activation. This effect of Zn2 on PTEN degra-
dation appeared to be specific since the potent phosphatase
inhibitor vanadyl sulfate and the EGF receptor ligand EGF did
not show significant effect on PTEN protein levels.
Previous studies have shown that the phosphorylation of the
PTEN COOH terminus regulates protein stability by modulat-
ing PTEN binding to PDZ-containing proteins or by other pos-
sible mechanisms (13, 18, 31, 55, 61). Recent studies employing
PTEN mutagenesis or biochemical analysis by mass spectros-
copy have identified a number of serine and threonine residues
as potential regulatory sites involved in protein stabilization
(31, 55, 61). However, the identified residues are not completely
consistent among the studies. In addition, the latest study
using MCF-7 cells has demonstrated that BMP-2-stimulated
increases in PTEN protein levels were independent of changes
in PTEN phosphorylation state and protein synthesis (57).
These data suggest that PTEN protein stability may be regu-
lated by multiple distinct post-translational modifications. It
remains to be determined whether Zn2 destabilizes PTEN
protein by reducing the phosphorylation of specific PTEN res-
idues or by an alternative mechanism.
Given that the phosphorylation of PTEN regulates its stabil-
ity, the identification of the responsible upstream protein ki-
nases has been the subject of great investigative effort. To date,
the protein kinase CK2 has been proposed as a PTEN kinase
(30, 55, 61). Our data showing that LY294002 blocked Zn2-
induced PTEN degradation, as well as Akt activation, impli-
cated the involvement of the PI3K/Akt pathway in PTEN reg-
ulation. A recent study suggested that Akt activation could
promote degradation of tuberin and FOXO3a via the protea-
some (62). Additional studies will investigate the possible link
between Akt activation and Zn2-induced PTEN degradation.
Apparently, the signaling downstream of PTEN was affected
by Zn2-induced PTEN degradation since pretreatment of cells
with MG132 significantly inhibited Zn2-induced Akt activa-
tion as well as PTEN degradation. However, the earlier phos-
phorylation of Akt (1 h after exposure) might result from the
slight inhibition of PTEN phosphatase activity by Zn2 (data
not shown). Early studies of PTEN showed that its activity was
able to promote cell cycle arrest and apoptosis and inhibit cell
motility, but more recent investigations revealed other func-
tional consequences of PTEN action, such as the effect on the
regulation of angiogenesis, non-insulin-dependent diabetes,
and inflammation (4, 13, 63). The fact that zinc ions could
down-regulate PTEN may provide some information in under-
standing the mechanisms of zinc-related pathophysiological
processes and disorders.
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